Goettingen, Germany, March 4, 2022 – With Jörn Tolstrup, PhD we strengthen our team. He joins Curexsys to be responsible for all clinical operations starting with the company’s first human clinical trial.

Christian Eckert, COO of Curexsys: “We are very happy to welcome Jörn Tolstrup to the Curexsys team. His extensive expertise in clinical operations and strong scientific background in the field of ATMPs and biologics will be an ideal complement and another step forward.

Jörn Tolstrup comes to Curexsys from Morphosys AG, Planegg, where he was responsible for clinical study management in two global clinical studies. Before that, he was responsible for two studies on hematological malignancies at Medigene AG, Munich.

He studied biology at the universities of Marburg and Würzburg, Germany, and received his doctorate (Dr. at the University Medical Center Göttingen, Department of Cellular Biochemistry).